

Revision date: 15-Dec-2006 Version: 1.1 Page 1 of 7

### IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Prazepam Tablets (10mg;20mg)

Trade Name: Demetrin; Centrac; Centrax; Reapam

Chemical Family: Mixture

Intended Use: Pharmaceutical product used as Antidepressant/antianxiety.

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	EU EINECS List	%
Maize starch	9005-25-8	232-679-6	*
Microcrystalline cellulose	9004-34-6	232-674-9	*
Colloidal silicon dioxide	7631-86-9	231-545-4	*
Magnesium stearate	557-04-0	209-150-3	*
Prazepam	2955-38-6	220-975-8	6.7 - 13.3

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Lactose	63-42-3	200-559-2	*

Additional Information: \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** Pale blue or white tablets.

Signal Word: WARNING

Statement of Hazard: Suspected of damaging fertility.

May cause central nervous system effects

**Additional Hazard Information:** 

**Short Term:**Not acutely toxic . Not expected to cause skin irritation ; eye irritation (based on components) . **Long Term:**Repeat-dose studies in animals have shown a potential to cause adverse effects on liver, male

reproductive system.

**Known Clinical Effects:** Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia,

confusion, tremors, headache, and gastrointestinal disturbances. This material has been shown to be secreted in low concentrations in human breast milk. The following effects are based on a chemically-related material: symptoms of dependence/withdrawal, insomnia,

amnesia, agitation, nightmares, hallucinations.

Material Name: Prazepam Tablets (10mg;20mg)

Revision date: 15-Dec-2006

Page 2 of 7

Version: 1.1

**EU Indication of danger:** Toxic to Reproduction; Category 3

**EU Hazard Symbols:** 



**EU Risk Phrases:** 

R62 - Possible risk of impaired fertility.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

# 4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

# 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride

and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not determined

### 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

**Protections:** 

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Prazepam Tablets (10mg;20mg) Page 3 of 7 Revision date: 15-Dec-2006 Version: 1.1

# 7. HANDLING AND STORAGE

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with **General Handling:** 

eyes. Avoid generating airborne dust.

**Storage Conditions:** Store at controlled room temperature. Protect from light.

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Maize starch

**OSHA - Final PELS - TWAs:** = 15 mg/m<sup>3</sup> TWA total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)** = 10 mg/m<sup>3</sup> TWA **Australia TWA**  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Microcrystalline cellulose

**OSHA - Final PELS - TWAs:**  $= 15 \text{ mg/m}^3 \text{ TWA}$ total

 $= 5 \text{ mg/m}^3 \text{ TWA}$ **ACGIH Threshold Limit Value (TWA)**  $= 10 \text{ mg/m}^3 \text{ TWA}$  $= 10 \text{ mg/m}^3 \text{ TWA}$ 

Colloidal silicon dioxide

**Australia TWA** 

**OSHA - Final PELs - Table Z-3 Mineral D:** (80)/(% SiO2) mg/m3 TWA

= 20 mppcf TWA **Australia TWA**  $= 2 \text{ mg/m}^3 \text{ TWA}$ 

Magnesium stearate

**ACGIH Threshold Limit Value (TWA)**  $= 10 \text{ mg/m}^3 \text{ TWA}$ except stearates of toxic metals

 $= 10 \text{ mg/m}^3 \text{ TWA}$ **Australia TWA** 

**Prazepam** 

Pfizer OEL TWA-8 Hr: 0.02 mg/m<sup>3</sup>

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Analytical Method:** Analytical method available for Prazepam. Contact Pfizer Inc for further information.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

**Personal Protective Equipment:** 

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

# 9. PHYSICAL AND CHEMICAL PROPERTIES:

**Physical State:** Tablet Color: Pale blue or white

Mixture Molecular Formula: **Molecular Weight:** Mixture

Material Name: Prazepam Tablets (10mg;20mg)

Revision date: 15-Dec-2006

Page 4 of 7

Version: 1.1

### 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.

Conditions to Avoid: Light

Incompatible Materials: No data available

# 11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Lactose

Rat Oral LD50 > 10 g/kg

Prazepam

 Mouse
 Oral
 LD50
 2.3 g/kg

 Rat
 Oral
 LD50
 >4 g/kg

 Rat
 IP
 LD50
 >2 g/kg

 Mouse
 IP
 LD50
 1 g/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Prazepam

35 Day(s) Rat Oral 35 mg/kg LOAEL Liver, Male reproductive system 12 Week(s) Dog No route specified 13.5 mg/kg/day NOAEL Liver

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Prazepam** 

Reproductive & Fertility Mouse Oral 0.02 % LOAEL Reproductive toxicity, Fetotoxicity

Reproductive & Fertility Rat No route specified 80 mg/kg LOAEL Reproductive toxicity, Fetotoxicity

Embryo / Fetal Development Rat Oral 250 mg/kg NOAEL Negative

Embryo / Fetal Development Rabbit No route specified 80 times human dose NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Genetic Toxicity Comments: Genetic toxicity tests were negative.

Material Name: Prazepam Tablets (10mg;20mg)

Revision date: 15-Dec-2006

Page 5 of 7

Version: 1.1

100 Holling 100 2000

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Prazepam

2 Year(s)Rat Oral, in feedNot carcinogenic2 Year(s)Mouse Oral, in feedNot carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

See below

Prazepam

IARC: Group 3

Colloidal silicon dioxide

IARC: Group 3

# 12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

# 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

# 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

EU Symbol: Xr

**EU Indication of danger:** Toxic to Reproduction; Category 3

**EU Risk Phrases:** 

R62 - Possible risk of impaired fertility.

**EU Safety Phrases:** 

S36/37 - Wear suitable protective clothing and gloves.

S53 - Avoid exposure - obtain special instructions before use.

**OSHA Label:** 

Material Name: Prazepam Tablets (10mg;20mg)

Revision date: 15-Dec-2006

Page 6 of 7

Version: 1.1

#### WARNING

Suspected of damaging fertility.

May cause central nervous system effects

### Canada - WHMIS: Classifications

### WHMIS hazard class:

D2a very toxic materials



Lactose

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List200-559-2

Maize starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-674-9

Colloidal silicon dioxide

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-545-4

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)PresentAustralia (AICS):PresentEU EINECS List209-150-3

Prazepam

Drug Enforcement Administration:Schedule IVAustralia (AICS):PresentStandard for the Uniform SchedulingSchedule 4

for Drugs and Poisons:

EU EINECS List 220-975-8

Additional Information: US DEA Schedule IV substance

# **16. OTHER INFORMATION**

Reasons for Revision: Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard

Identification. Updated Section 8 - Exposure Controls / Personal Protection.

**Prepared by:** Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Material Name: Prazepam Tablets (10mg;20mg)

Revision date: 15-Dec-2006

Page 7 of 7

Version: 1.1

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**